Super fund HESTA reveals landmark $4.4 million investment in biotech startup Inventia Life Science
Healthcare superannuation fund HESTA has revealed that it chipped in $4.4 million to a $35 million Series B for Sydney biotech startup Inventia Life Science. The deal marks the first direct investment made by a super fund into an early-stage startup. The industry has previously tipped their cash into venture capital funds, with the VCs… Read more »